Prognostic factors and survival in patients under 18 years of age with Ewing sarcoma family tumors: A 10-year experience
DOI:
https://doi.org/10.24265/horizmed.2017.v17n4.02Keywords:
Ewing sarcoma, Primitive peripheral neuroectodermal tumors, Prognosis, SurvivorshipAbstract
Objective: To describe the clinical and epidemiological characteristics, and to determine the prognostic factors, event-free survival (EFS) and overall survival (OS) of patients with Ewing Sarcoma family of tumors (ESFT). Materials and methods: retrospective study carried out in patients under 18 years of age with TFSE, seen at the Pediatric and Adolescent Oncology Unit of the Edgardo Rebagliati Hospital between 2006 and 2016. The descriptive analysis was performed by frequency distribution. Kaplan-Meier curves were used for the analysis of SLE and OS. Univariate and multivariate analysis was performed according to Cox regression model for demographic, clinical and surgical variables, and prognostic factors. The measure of strength of association was expressed as hazard ratio (HR) and 95% confidence interval (95% CI), and p<0.05 was considered for significant differences. Results: Twenty-nine cases of TFSE were presented. The median age was 9 years (range 2-17), 55% were male. The most frequent location was the pelvis (31%). Fifty-nine percent had metastases at diagnosis. The 3-year EFS in localized ESFT was 40.4% (±14.4 ES) and with metastases, 14.6% (±12.2, ES). The 3-year OS in localized TFSE was 53.9% (±17.8 ES) and in metastatic disease, 15.1% (±9.7, ES). Tumor size ≥5cm (HR 14.84, p=0.01) and the presence of metastases at debut (HR 3.23, p=0.01) were independent prognostic factors for worse OS. There was no significant difference in relation to prognosis according to sex, age, histologic type, surgical edge involvement or tumor location. Conclusions: ESFTs are highly aggressive. Prognostic factors contributing to lower EFS and OS are the presence of metastases at disease debut and tumor size ≥5cm.
Downloads
References
Balamuth N, Womer R. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184–92.
Madero L. Sarcoma de Ewing. En: Madero L, Lassaletta A, Sevilla J, editores. Hematología y oncología pediátrica. 3a Edición. Madrid: Ergon; 2015. p. 651-63.
MINSA - Instituto Nacional de Enfermedades Neoplásicas. Registro de cáncer de Lima Metropolitana, Incidencia y Mortalidad 2010-2012.pdf [Internet]. [citado el 25 de setiembre del 2017]; Disponible en: http://bvs.minsa.gob.pe/local/MINSA/3774.pdf
Rodríguez-Galindo C, Liu T, Krasin M, Wu J, Billups C, Daw N, et al. Analysis of prognostic factors in ewing sarcoma family of tumors. Cáncer. 2007;110(2):375–84.
Cotterill S, Ahrens S, Paulussen M, Jürgens H, Voûte P, Gadner H, et al. Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative. Journal of Clinical Oncology. 2000; 18(17): 3108-14.
Verma V, Denniston KA, Lin CJ, Lin C. A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors. Front Oncol. 2017;7: 82
Karski EE, McIlvaine E, Segal MR, Krailo M, Grier HE, Granowetter L, et al. Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer. 2016;63(1):47–53.
Bellan D, Garcia R, Garcia J, Petrilli M, Viola D, Schoedl M, et al. et al. Sarcoma de ewing: epidemiología e prognóstico dos pacientes tratados no instituto de oncología pediátrica, iop-graacc-unifesp. Rev Bras Ortop [Internet] 2012 [citado el 27 de julio del 2017]; Disponible en: http://www.repositorio.unifesp.br/handle/11600/6813
Xie C-F, Liu M-Z, Xi M. Extraskeletal Ewing’s sarcoma: a report of 18 cases and literature review. Chin J Cáncer 2010;29(4):420–4.
Delaplace M, Lhommet C, de Pinieux G, Vergier B, de Muret A, Machet L. Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome. Br J Dermatol. 2012;166(4):721–6.
Sadiq M, Ahmad I, Shuja J, Ahmad K. Primary Ewing sarcoma of the kidney: a case report and treatment review. CEN Case Rep.2017:1-4
Oberlin O, Deley M, Bui B, Gentet J, Philip T, Terrier P, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001; 85(11): 1646–54.
Raciborska A, Bilska K, Drabko K, Chaber R, Sobol G, Pogorzała M, et al. Validation of a multi-modal treatment protocol for Ewing sarcoma—A report from the polish pediatric oncology group. Pediatr Blood Cancer. 2014; 61(12): 2170–4.
Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, et al. Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer Oxf Engl. 2004;40(1):73–83.
Duchman K, Gao Y, Miller B. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189–95.
Huh W, Daw N, Herzog C, Munsell M, McAleer M, Lewis V. Ewing sarcoma family of tumors in children younger than 10 years of age. Pediatr Blood Cancer. [Internet] 2017 [citado el 27 de julio del 2017]; 64(4). Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/pbc.26275/abstract
Applebaum M, Worch J, Matthay K, Goldsby R, Neuhaus J, West D, et al. Clinical features and outcomes in patients with extraskeletal ewing sarcoma. Cancer. 2011;117(13):3027–32.
Gupta A, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, et al. Clinical outcome of children and adults with localized Ewing sarcoma. Cancer 2010;116(13):3189–94.
Kissane J, Askin F, Foulkes M, Stratton L, Shirley S. Ewing’s sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing’s Sarcoma Study. Hum Pathol. 1983;14(9):773–9.
Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn- Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol Off J Eur Soc Med Oncol. 1998;9(3):275–81.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
